Forsta AP Fonden Has $37.10 Million Stake in Amgen Inc. $AMGN

Forsta AP Fonden lowered its position in Amgen Inc. (NASDAQ:AMGN) by 2.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 113,340 shares of the medical research company’s stock after selling 2,660 shares during the period. Forsta AP Fonden’s holdings in Amgen were worth $37,097,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Anfield Capital Management LLC lifted its position in shares of Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares during the period. Dogwood Wealth Management LLC lifted its position in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares during the period. Board of the Pension Protection Fund acquired a new position in shares of Amgen in the 4th quarter worth approximately $26,000. Manning & Napier Advisors LLC lifted its position in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares during the period. Finally, Olistico Wealth LLC acquired a new position in shares of Amgen in the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.85% of the stock is currently owned by insiders.

Amgen Stock Performance

NASDAQ:AMGN opened at $336.79 on Friday. The company has a fifty day moving average of $342.53 and a 200-day moving average of $345.33. The firm has a market capitalization of $181.77 billion, a P/E ratio of 23.44, a P/E/G ratio of 3.38 and a beta of 0.44. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.37 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. Amgen’s dividend payout ratio is presently 70.15%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AMGN. Piper Sandler dropped their price target on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating on the stock in a research report on Thursday, May 14th. Cantor Fitzgerald restated a “neutral” rating and issued a $350.00 price target on shares of Amgen in a research report on Wednesday, April 8th. Mizuho lifted their price objective on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Rothschild & Co Redburn lifted their price objective on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Finally, TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $355.19.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.